2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.104 (Poster) Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases

PP01.104 (Poster) Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases

Pdf Summary

The majority of non-small cell lung cancer (NSCLC) cases are attributed to MET exon 14 skipping mutations (METex14) and MET amplification (METamp). However, it is unclear how these alterations affect treatment response. Vebreltinib, a MET tyrosine kinase inhibitor, has shown promise in targeting METex14 NSCLC. In this study, the authors analyzed the distribution of MET gene copy number (GCN) in METex14 NSCLC patients from public databases and ongoing clinical trials of vebreltinib (SPARTA-II and KUNPENG). They also assessed the efficacy and safety of vebreltinib in METex14 NSCLC with and without METamp. The data showed that the distribution of MET GCN status in the vebreltinib trials was similar to that in public databases. Vebreltinib demonstrated efficacy in METex14 NSCLC patients with or without METamp, particularly in those with GCN4. The overall response rate was 64.5% in patients with GCN4 and 65.4% in patients with GCN6. The median duration of response was 15.9 months. Treatment-related adverse events were generally acceptable, with edema and alanine aminotransferase increase being the most common. The study concluded that vebreltinib is effective in treating METex14 NSCLC and has an acceptable safety profile. These findings contribute to a better understanding of the distribution and treatment response of METex14 NSCLC patients in real-world populations. The results support the use of vebreltinib as a targeted therapy for METex14 NSCLC, regardless of METamp status.

Asset Subtitle

Peony Yu

Keywords

non-small cell lung cancer

NSCLC

METex14

METamp

vebreltinib

MET tyrosine kinase inhibitor

MET gene copy number

GCN4

efficacy

safety